DDInter1355 DDInter1435
Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. Compared to cisplatin the two amine groups are replaced by diamino cyclohexane (DACH) group to provide a greater antitumor effect. However, this leads to poorer water solubility, which was compensated by the addition of the chloride moieties. Due to this chemical moiety, oxaliplatin readily undergoes non-enzymatic biotransformation, thus complicating oxaliplatin's pharmacokinetics. Like most platinum-based compounds, oxaliplatin's mechanism of action is primarily through DNA damage through DNA crosslinking, particularly intrastrand and interstrand crosslinking. However, due to the structure of oxaliplatin, its adducts make the binding of mismatch repair protein to DNA harder compared to cisplatin or carboplatin's adducts, resulting in greater cytotoxic effects. The
Pexidartinib is a selective tyrosine kinase inhibitor that works by inhibiting the colony-stimulating factor (CSF1)/CSF1 receptor pathway. Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August 2019 as the first systemic therapy for adult patients with symptomatic tenosynovial giant cell tumor. Tenosynovial giant cell tumor is a rare form of non-malignant tumor that causes the synovium and tendon sheaths to thicken and overgrow, leading to damage in surrounding joint tissue.[A182240,L7901] Debilitating symptoms often follow with tenosynovial giant cell tumors, along with a risk of significant functional limitations and a reduced quality of life in patients. While surgical resection is a current standard of care for tenosynovial giant cell tumor, there are tumor types where surgeries are deemed clinically ineffective with a high risk of lifetime recurrence. Pexidartinib works by blocking the immune responses that are activated in tenosynovial giant cell tumors. In clinical trials, pexidartinib was shown to promote improvements in patient symptoms and functional outcomes in TGCT. Pexidartinib is available in oral formulations and it is commonly marketed as Turalio.
Oxaliplatin {u} (Compound) binds {v} (Gene) ATP7B
Oxaliplatin {u} (Compound) is included by {v} (Pharmacologic Class) Platinum-containing Compounds
Oxaliplatin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sulfamethoxazole
Oxaliplatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Oxaprozin
Oxaliplatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Floxuridine
Oxaliplatin {u} may lead to a major life threatening interaction when taken with {v} Escitalopram
Oxaliplatin {u} may lead to a major life threatening interaction when taken with {v} Dofetilide
Oxaliplatin (Compound) binds ATP7B (Gene)
Oxaliplatin (Compound) is included by Platinum-containing Compounds (Pharmacologic Class)
Oxaliplatin may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole
Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Oxaprozin
Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Floxuridine
Oxaliplatin may lead to a major life threatening interaction when taken with Escitalopram
Oxaliplatin may lead to a major life threatening interaction when taken with Dofetilide